Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Mashaal A.R.; El-Hameed M.A.; El Ray A.A.; Diab T.M.; Dawood R.M.; Shemis M.A.; Seyam M.

Journal: Asian Pacific Journal of Cancer Prevention

Publisher: Asian Pacific Organization for Cancer Prevention

Publication Date: 1 September 2022

Volume / Issue: Volume 23 / Issue 9

Pages: 2965–2971

ISSN: 15137368

DOI: 10.31557/APJCP.2022.23.9.2965

Scopus: View on Scopus

PubMed: 36172658

Document Type: Article

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Mashaal A.R., Hepatogastroentrology, Theodor Bilharz Research Institute, Egypt; El-Hameed M.A., Hepatogastroentrology, Theodor Bilharz Research Institute, Egypt; El Ray A.A., Hepatogastroentrology, Theodor Bilharz Research Institute, Egypt; Diab T.M., Department of Immunoparasitology, Theodor Bilharz Research Institute, Egypt; Dawood R.M., Department of Microbial Biotechnology, Biotechnology Research Institute, National Research Centre, Egypt; Shemis M.A., Department of Biochemistry & Mol. Biology, Theodor Bilharz Research Institute, Egypt; Seyam M., Hepatogastroentrology, Theodor Bilharz Research Institute, Egypt


Abstract

Background: Occult hepatitis C virus (HCV) infection (OCI) is diagnosed based on the detection of HCV-RNA in non-serum reservoirs, such as peripheral blood mononuclear cells (PBMCs) and/or hepatocytes with undetectable HCV-RNA in the serum. The current study was designed to shed more light on the presence of occult HCV in a population of cases who achieved an SVR after receiving treatments for HCV-infection and its significance. Methods: This cross-sectional study evaluated 111 chronic HCV patients treated at Theodor Bilharz Research Institute, Egypt and achieved a sustained virological response (SVR) 12 -24 weeks after treatment with Direct acting antiviral drugs (DAAs). The treatment lasted 12 or 24 weeks using generic medications including Sofosbuvir (SOF) 400 mg/day and Daclatasvir (DCV) 60 mg/day ± weight-based Ribavirin (RBV) 600-1000 mg/day. After achieving the SVR 12 -24 weeks, all patients were subjected to clinical examination and full laboratory investigations. All the candidates were assessed for fibrosis pre/post-treatment by transient elastography (Fibroscan©). Eighty-seven patients (78.4%) received dual therapy (SOF/DCV) and 24 patients (21.6%) received triple therapy (SOF/DCV/RBV). One hundred and seven patients received the regimen for 12 weeks (96.4%) and only four patients received the regimen for 24 weeks (3.6%). All patients were examined in terms of HCV RNA in plasma and PBMCs. Results: Nine patients (8.1%) were positive for PBMCs HCV RNA. The presence of Occult HCV infection (OCI) was significantly correlated with age, level of AFP, and the degree of liver stiffness. Conclusion: The OCI was present in 8.1% of the patients who achieved an SVR 12 – 24 weeks. These patients were mostly aged and with elevated AFP and advanced fibrosis. Monitoring and follow-up of those patients may help to assess the outcomes. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.


Keywords

Acting antiviral agents (daas); Direct; Hepatitis c virus (hcv); Occult hepatitis c virus infection (oci); Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; alpha fetoprotein; antivirus agent; carbamic acid derivative; daclatasvir; imidazole derivative; pyrrolidine derivative; chronic hepatitis C; combination drug therapy; cross-sectional study; epidemiology; genetics; human; mononuclear cell


Citation Information

Scopus Citations: 2


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]